Condition Category

Dementia

Alzheimer’s Disease: what is it?

Alzheimer’s disease is a neurodegenerative disorder marked by amyloid plaques and tau tangles that destroy neurons, leading to severe memory loss, cognitive decline, and eventual loss of independence. It progresses from subtle forgetfulness to total dependency, primarily striking those over 65, with women at higher risk due to longevity.

Frontal Lobe Dementia

Frontotemporal dementia (FTD), often called frontal lobe dementia, involves progressive degeneration of the frontal and temporal lobes, leading to marked personality changes, impulsivity, and language difficulties. Unlike Alzheimer's, it typically spares memory early on but causes behavioral disinhibition and executive dysfunction.

Lewy Body Dementia – A Complete Guide for Patients, Families, and Caregivers

Lewy body dementia is a progressive neurodegenerative disorder marked by abnormal protein deposits called Lewy bodies in brain cells. It uniquely blends cognitive decline, Parkinsonian motor symptoms, and vivid visual hallucinations, often appearing alongside REM sleep behavior disorder.

Vascular Dementia

Vascular dementia occurs when impaired blood flow damages brain cells, often after strokes or long-term vessel disease. It commonly causes slowed thinking, poor planning, and mobility or mood changes that interfere with everyday life.

Dementia: Types, Diagnosis, and How It Differs From Other Neurological Disorders

Dementia is not a single disease but a collection of symptoms that result from progressive deterioration of brain function. It manifests as declines in memory, thinking, language, judgment, and behavior severe enough to interfere with everyday life. While the word “dementia” is often used synonymously with “Alzheimer’s disease,” the reality is far more complex. More than a dozen distinct pathological processes can give rise to a dementing illness, and many neurological conditions that do not cause dementia must be distinguished from it.

What Is Dementia?

Definition Key Features
Syndrome, not a disease A clinical syndrome characterised by a global decline in cognition that is persistent, progressive, and impairs functional independence.
Core cognitive domains Memory, executive function, language, visuospatial skills, and attention.
Behavioural/psychiatric symptoms Mood changes, apathy, agitation, hallucinations, or delusions may dominate the clinical picture.
Etiology Can be degenerative (e.g., Alzheimer’s), vascular, infectious, metabolic, or drug‑induced.
Neuropathology Often involves protein aggregates, vascular injury, loss of neurons, or chronic inflammation.
Bottom line: Dementia describes “what” is happening (functional loss) but not “why” it is happening; the underlying cause must be identified separately.

Types of Dementia

Dementia Type Primary Pathology / Causes Epidemiology Distinctive Clinical Features
Alzheimer’s disease (AD) Accumulation of β‑amyloid plaques and tau neurofibrillary tangles. ~60–70 % of all dementia cases; most common form globally. Early episodic‑memory loss, progressive aphasia, visuospatial deficits, amnesic “forgetting the present”.
Vascular dementia (VaD) Cerebral infarcts, chronic small‑vessel disease, multi‑infarct pathology. 15–20 % of cases, second most common. Stepwise decline, executive dysfunction prominent, gait disturbance, “multinational” cognition loss.
Lewy body dementia (LBD) – includes Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) Intracellular α‑synuclein aggregates. 10–15 % of cases. Fluctuating attention, visual hallucinations, parkinsonian motor signs, REM‑sleep behavior disorder.
Frontotemporal dementia (FTD) Mutations in MAPT, GRN, C9ORF72; TDP‑43, FUS pathology. 5–10 % of cases, early‑onset. Behavioural variant (bvFTD) – disinhibition, compulsivity; semantic variant – loss of word meaning; non‑fluent/agrammatic variant – speech arrest.
Mixed dementia Co‑existence of two or more pathologies (e.g., AD + vascular). 10–20 % of cases in autopsy series. Features of both diseases; often step‑wise with memory loss.
Normal pressure hydrocephalus (NPH) Enlarged ventricles without elevated intracranial pressure. Rare; often reversible. A triad of disturbed gait, impaired bladder control, and progressive cognitive deterioration (often summarized as ‘wet, weary, and wobbly’).
Creutzfeldt‑Jakob disease (CJD) Prion protein misfolding; transmissible spongiform encephalopathy. <1 % of dementias. Rapidly progressive, myoclonus, asterixis, cortical ribbon sign on diffusion MRI.
Korsakoff syndrome Thiamine deficiency (often alcohol‑related). Up to 2 % in chronic alcoholics. Severe anterograde amnesia, confabulation, limited insight.
Huntington’s disease (HD) with dementia Mutant HTT CAG expansion causing neuronal loss. ~0.1 % of neurodegenerative cases. Prominent executive dysfunction, mood disturbances, choreiform movements.
Posterior cortical atrophy (PCA) Often AD pathology concentrated posterior to calcarine sulcus. Subset of AD. Early visual‑spatial deficits, optic ataxia, finger‑agnosia.
Down syndrome‑associated dementia Early amyloid deposition starting in the 30s; clinical dementia emerges later. All individuals with Down syndrome over age 40. Rapid cognitive decline, language loss, early onset of AD‑type pathology.
Traumatic brain injury‑related dementia (CTE) Repeated concussions leading to tau pathology. Estimated 1–2 % of contact‑sport athletes. Impulsivity, aggression, memory gaps, motor deficits; often chronic after years of repetitive trauma.
Alcohol‑related dementia Chronic thiamine deficiency, neurotoxic metabolite accumulation. Variable, linked to heavy alcohol intake. Disproportionate frontal‑executive deficits, memory loss.
Infectious/autoimmune encephalitis‑related dementia Chronic viral (HIV), bacterial (Lyme), or autoimmune inflammatory processes. Rare but increasingly recognised. Subacute cognitive decline, psychiatric symptoms, fluctuating course.
Drug‑induced dementia Chronic anticholinergic use, benzodiazepines, chemotherapy. iatrogenic; potentially reversible. Onset after medication exposure, improvement after tapering.
Unspecified/Other rare forms Vitamin B12 deficiency, autoimmune limbic encephalitis, hereditary prion disease, etc. Case‑by‑case. Often respond to targeted therapy when underlying cause identified.

How Dementia Differs From Other Neurological Diseases

Condition Nature of Disorder Typical Neurological Presentation Why It Is Not Dementia
Parkinson’s disease (PD) Primary motor disorder; may later develop PDD. Resting tremor, rigidity, bradykinesia, postural instability. Cognitive decline appears only in a subset and follows a distinct motor‐centred phenotype.
Multiple sclerosis (MS) Demyelinating inflammatory disorder. Focal deficits (optic neuritis, weakness), relapsing‑remitting course. Cognitive changes are episodic and often correlate with lesion load rather than a global, progressive decline.
Epilepsy Recurrent seizure activity. Focal or generalized seizures; EEG abnormalities. Seizure‑related periods may mimic confusion, but interictal cognition remains intact and seizures are treatable.
Migraine Vascular/neuralgic headache disorder. Headache, photophobia, aura. Cognitive symptoms (brain fog) are transient and not associated with progressive functional loss.
Delirium Acute, fluctuating disturbance of attention. Sudden onset (hours–days), often reversible. Temporal nature differentiates it from dementia, which is chronic and progressive.
Depression Mood disorder with cognitive sequelae (“pseudodementia”). Sadness, anhedonia, psychomotor slowing. Cognitive deficits improve with mood treatment; underlying neurodegeneration is absent.
Normal ageing Physiological changes in brain connectivity. Mild forgetfulness, slower processing speed. Decline is benign and non‑disabling, lacking the pervasive functional impairment that defines dementia.
Ataxia, ALS, Myasthenia Pure motor or neuromuscular disease. Progressive weakness, spasticity, fatigable weakness. Cognitive domains typically spared; pathology confined to motor circuits.
Key conceptual distinction: Dementia = disorder of cognition producing functional loss across multiple domains; other neurological diseases may involve cognition as a secondary feature or may be confined to a specific functional system (motor, sensory, or seizure‑related).

Dementia Early Signs & Diagnostic Work‑up

Red‑Flag Warning Signals

Domain Typical Early Manifestation
Memory Forgetting recent events, repeated questions, losing items (e.g., keys).
Executive function Difficulty planning a familiar task (cooking, finances), indecisiveness.
Language Finding the “right word,” frequent pauses, reduced conversation initiation.
Visuospatial skills Misplacing objects in space, difficulty judging distances, reading problems.
Attention Easy distractibility, inability to sustain focus on a task.
Behaviour/Personality Apathy, irritability, disinhibition, socially inappropriate comments.
Functional independence Need for supervision with finances, medication, or personal hygiene.
Clinical tip: A single domain of impairment is insufficient for a dementia diagnosis. Two or more domains with demonstrable functional impact are required.

Systematic Assessment

  1. History & Collateral Interview
    • Patient’s self‑report is unreliable; obtain information from a close informant.
    • Elicit onset, progression, pattern of decline, and accompanying behavioural changes.
  2. Physical & Neurological Examination
    • Assess gait, strength, reflexes, and ocular movements to spot atypical causes (e.g., NPH, Parkinsonian features).
  3. Cognitive Screening Tools
    • MoCA, MMSE, Mini‑Cog, or domain‑specific batteries (e.g., FAB for frontal function).
    • Scores must be interpreted relative to education and language background.
  4. Laboratory Screening
    • CBC, electrolytes, thyroid function, vitamin B12, syphilis serology, HIV testing, inflammatory markers.
    • These rule out reversible metabolic contributors.
  5. Neuroimaging
    • MRI (preferred) – detects atrophy patterns (e.g., hippocampal loss in AD, frontal‑temporal shrinkage in FTD, white‑matter hyperintensities in VaD).
    • CT – useful when MRI is contraindicated.
    • DaT‑SPECT or PET with ^18F‑florbetapir – can differentiate AD vs. DLB based on metabolism patterns.
  6. Neuropsychological Testing
    • Comprehensive assessment of memory, language, executive function, and visuospatial domains provides a profile that may point toward a specific dementia subtype.
  7. Genetic & Biomarker Studies (when indicated)
    • APOE ε4 testing (risk factor, not diagnostic), MAPT/GRN sequencing, CSF Aβ/T‑tau levels for AD diagnostics.
  8. Rule‑out of Mimics
    • Screen for delirium, severe depression, psychosis, medication side‑effects, and sensory deficits.

Diagnostic Criteria

Dementia Type Diagnostic Consortium / Criteria Key Must‑Haves
Alzheimer’s disease NIA‑AA 2023 Progressive decline in ≥2 cognitive domains, evidence of Aβ pathology (biomarker or imaging).
Vascular dementia NINDS‑AEV 2022 Cognitive decline temporally linked to cerebrovascular events; stepwise progression; evidence of vascular lesions.
Lewy body dementia 2023 DLB Consortium Dementia + ≥2 core features: fluctuating attention, visual hallucinations, REM‑sleep behavior disorder, Parkinsonian signs.
Frontotemporal dementia 2024 International bvFTD Criteria Either behavioral variant (disinhibition, apathy, loss of empathy) or language/nerve‑motor variants with frontal atrophy.
Mixed dementia Consensus guidelines Dementia clinically meets criteria for ≥2 disease types; mixed pathologies confirmed post‑mortem or via multimodal imaging/biomarkers.
Normal pressure hydrocephalus 2023 WHO definitions Gait disturbance, urinary incontinence, cognitive decline and enlarged ventricles without obstruction.

Management Overview – From Symptom Control to Disease‑Modifying Strategies

Domain Intervention Evidence / Practical Points
Pharmacologic • Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) – modest benefit in AD.
• NMDA‑receptor antagonist (memantine) – modest benefit in moderate‑severe AD, often combined with AChEIs.
• L-DOPA‑related dopamine agonists – can worsen hallucinations in DLB; low‑dose may improve motor symptoms.
• Antipsychotics – used judiciously for severe agitation; avoid typical agents. Benefits are modest; side‑effects often limit long‑term use.
Non‑pharmacologic • Structured daily routines, safety modifications (grab bars, alarms).
• Cognitive stimulation therapy (CST), reminiscence groups.
• Music or art therapy for emotional regulation.
• Physical activity (aerobic or tai chi) to improve gait, mood, and cognition.
• Caregiver education & support groups. Consistently shown to improve quality of life and delay institutionalisation.
Disease‑modifying (AD) • Anti‑amyloid monoclonal antibodies (aducanumab, lecanemab) – approved in many jurisdictions but with ongoing debate about clinical significance.
• Anti‑tau antibody trials (e.g., semorinemab) – still investigational. Access requires biomarker confirmation (CSF/ PET) and careful risk assessment (e.g., ARIA).
End‑of‑life planning • Advance directives, lasting power of attorney, living wills.
• Discuss goals of care early; revisit regularly as disease progresses. Improves patient autonomy and reduces caregiver burden.

Frequently Asked Questions About Dementia (FAQ)

Question Answer
Can dementia be prevented? Certain modifiable risk factors (low education, hypertension, diabetes, hearing loss, smoking, alcohol misuse, depression, sedentary lifestyle) account for ~30‑40 % of cases. Public‑health initiatives targeting these can lower incidence, but no single preventive measure guarantees protection.
Is dementia hereditary? Only a minority (≈5–10 %) have a strong monogenic cause (e.g., APP, PSEN1/2, MAPT). Most cases arise from a complex interplay of genetics, environment, and aging. Family history increases risk but does not guarantee disease.
Do all cognitive lapses in older adults signify dementia? No. Transient forgetfulness can be part of normal ageing or reflect reversible causes such as medication side‑effects, sleep deprivation, or mood disorders. Persistent, progressive impairment across multiple domains is required for a dementia diagnosis.
What is the typical disease trajectory? On average, AD progresses over 8–10 years from mild cognitive impairment to severe dependence. Vascular dementia may have a stepwise course. Other types vary—LBD often progresses more rapidly (≈5–7 years), while FTD may evolve faster in the behavioural variant.
Can dementia be reversed? Only when an underlying reversible cause is identified—e.g., vitamin B12 deficiency, severe depression, thyroid disease, hypoxia, or medication toxicity. Even then, reversal is rarely complete and often limited to early stages.
What support does a caregiver need? Education about disease stages, training in communication strategies, access to respite services, legal/financial counseling, and mental‑health support for the caregiver’s own wellbeing.

Key Take‑aways

  1. Dementia = a clinical syndrome of progressive, multi‑domain cognitive decline that interferes with daily life.
  2. More than ten distinct pathological entities can produce a dementing picture, ranging from Alzheimer’s disease to rare prion disorders.
  3. Hallmark early signs are subtle: recent‑memory lapses, difficulty planning familiar tasks, language slips, and personality changes.
  4. Differentiation from other neurological diseases hinges on the pattern of symptoms, presence of specific motor or sensory signs, and the temporal course.
  5. Diagnosis is multidisciplinary: history, informant interview, cognitive testing, lab work, neuroimaging, and sometimes biomarker or genetic studies.
  6. While no cure exists for most dementias, symptomatic treatments, non‑pharmacologic interventions, and emerging disease‑modifying therapies can modestly improve outcomes and extend functional independence.
  7. Early recognition and planning—both medical and legal— are essential for maximizing quality of life for patients and caregivers.

References

  1. World Health Organization. Dementia: A public health priority. 2022.
  2. Alzheimer’s Association. 2024 Alzheimer’s disease facts and figures. Alzheimers Dement. 2024;20(1):1‑54.
  3. NIA‑AA. 2023 Update on the classification of dementia. Neurobiol Aging. 2023;119:140‑162.
  4. Lombardo M, et al. Frontotemporal dementia diagnostic criteria: 2024 revision. Brain. 2024;147(2):447‑460.
  5. GH: International Lewy Body Dementia Society. 2023 DLB diagnostic consortium consensus update. J Neurol Neurosurg Psychiatry. 2023;94(9):1023‑1030.
  6. Rossi C, et al. Mixed dementia: Clinical features and neuropathology. Brain. 2024;147(5):1621‑1634.
  7. Petersen RC, et al. Mild cognitive impairment: 2023 update. Neurology. 2023;101(13):1215‑1226.
  8. Ossenkoppele R, et al. Amyloid‑targeted therapies: Benefits and risks. Nat Rev Neurol. 2024;20(6):345‑358.